DNB Asset Management AS Buys 14,924 Shares of Xenon Pharmaceuticals Inc. $XENE

DNB Asset Management AS lifted its stake in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) by 6.4% in the third quarter, according to the company in its most recent filing with the SEC. The fund owned 249,081 shares of the biopharmaceutical company’s stock after buying an additional 14,924 shares during the quarter. DNB Asset Management AS owned about 0.32% of Xenon Pharmaceuticals worth $10,001,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Elevation Point Wealth Partners LLC acquired a new stake in Xenon Pharmaceuticals during the second quarter worth approximately $32,000. Osaic Holdings Inc. increased its stake in shares of Xenon Pharmaceuticals by 541.4% during the second quarter. Osaic Holdings Inc. now owns 1,225 shares of the biopharmaceutical company’s stock worth $40,000 after purchasing an additional 1,034 shares during the period. L1 Capital Pty Ltd bought a new stake in Xenon Pharmaceuticals in the 2nd quarter valued at $41,000. State of Wyoming grew its holdings in Xenon Pharmaceuticals by 112.8% in the 3rd quarter. State of Wyoming now owns 1,151 shares of the biopharmaceutical company’s stock valued at $46,000 after buying an additional 610 shares in the last quarter. Finally, Amalgamated Bank acquired a new position in Xenon Pharmaceuticals in the 2nd quarter valued at $81,000. Institutional investors and hedge funds own 95.45% of the company’s stock.

Xenon Pharmaceuticals Stock Down 3.8%

NASDAQ XENE opened at $43.23 on Friday. The company has a market cap of $3.34 billion, a price-to-earnings ratio of -9.92 and a beta of 0.96. The business has a 50 day moving average price of $42.49 and a 200-day moving average price of $41.04. Xenon Pharmaceuticals Inc. has a 52 week low of $26.74 and a 52 week high of $46.99.

Xenon Pharmaceuticals (NASDAQ:XENE) last issued its quarterly earnings data on Thursday, February 26th. The biopharmaceutical company reported ($1.31) EPS for the quarter, missing the consensus estimate of ($1.20) by ($0.11). During the same period in the previous year, the firm earned ($0.84) earnings per share. On average, equities research analysts anticipate that Xenon Pharmaceuticals Inc. will post -3.1 earnings per share for the current year.

Wall Street Analyst Weigh In

XENE has been the subject of a number of recent research reports. Chardan Capital raised shares of Xenon Pharmaceuticals to a “strong-buy” rating in a research report on Wednesday, November 19th. Needham & Company LLC lifted their price objective on shares of Xenon Pharmaceuticals from $55.00 to $58.00 and gave the company a “buy” rating in a research note on Friday. Wells Fargo & Company lifted their price target on shares of Xenon Pharmaceuticals from $48.00 to $49.00 and gave the company an “overweight” rating in a report on Friday. Cantor Fitzgerald reiterated an “overweight” rating and issued a $55.00 target price on shares of Xenon Pharmaceuticals in a research report on Tuesday, November 4th. Finally, Stifel Nicolaus set a $66.00 price objective on Xenon Pharmaceuticals in a report on Tuesday, February 10th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $55.50.

More Xenon Pharmaceuticals News

Here are the key news stories impacting Xenon Pharmaceuticals this week:

• Positive Sentiment: Two analyst upgrades lift sentiment — Needham raised its price target to $58 with a Buy rating and Wells Fargo nudged its target to $49 with an Overweight rating, implying meaningful upside from current levels, which supports longer-term investor interest. Analyst Price Target Raises (Benzinga)
• Positive Sentiment: Company update highlights near-term clinical catalysts and strong pro forma cash runway — Xenon reiterated a Phase 3 topline readout for azetukalner (X-TOLE2) expected in early March and reported pro forma cash (~$716M) that management says extends runway into H2 2027, reducing near-term financing risk and keeping the pipeline-funded. Xenon Reports Q4 and Full Year 2025 Financial Results and Provides Business Update
• Neutral Sentiment: Analyst/press commentary stresses pipeline focus despite higher R&D — Coverage (e.g., Zacks) notes a wider Q4 loss driven by a 47% jump in R&D spend but underscores ongoing late‑stage azetukalner trials and early-stage pain programs; useful context but not an immediate stock mover beyond the earnings reaction. Xenon Q4 Loss Wider Than Expected, Pipeline Development in Focus
• Negative Sentiment: Refreshed $400M at-the-market (ATM) equity program — Xenon filed to refresh an ATM capacity, which increases the potential for share issuance. While it provides financing optionality, investors often view ATM refreshes as a near-term dilution risk that can pressure the stock. Xenon Pharmaceuticals Refreshes $400 Million ATM Equity Program
• Negative Sentiment: Q4 EPS missed estimates — Xenon reported ($1.31) EPS vs. consensus ($1.20), a larger loss year-over-year; the miss likely contributed to intra-day selling despite the pipeline updates. Xenon Reports Q4 and Full Year 2025 Financial Results (Press Release PDF)

Insider Activity at Xenon Pharmaceuticals

In other Xenon Pharmaceuticals news, CEO Ian Mortimer sold 40,000 shares of the company’s stock in a transaction dated Friday, January 2nd. The shares were sold at an average price of $44.43, for a total value of $1,777,200.00. Following the completion of the sale, the chief executive officer directly owned 6,000 shares of the company’s stock, valued at approximately $266,580. This represents a 86.96% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders have sold a total of 65,205 shares of company stock valued at $2,919,762 in the last three months. Corporate insiders own 4.07% of the company’s stock.

Xenon Pharmaceuticals Profile

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.